[Leponex, 10 years after -- a clinical review]

Area of Science:

• Psychiatry and Pharmacology
• Neuroscience
• Clinical Therapeutics

Context:

• Clozapine represents a significant advancement in schizophrenia treatment, serving as a benchmark for novel antipsychotics.
• Recent indications for clozapine include Parkinson's disease psychosis, necessitating an update on its efficacy in schizophrenia.
• The unique pharmacological profile of clozapine, including low D2 receptor occupancy, warrants further investigation.

Purpose:

• To systematically review current clinical evidence on clozapine's efficacy and safety in schizophrenia treatment.
• To critically analyze clozapine's effectiveness in managing refractory positive symptoms, negative symptoms, and neurocognitive deficits.
• To assess clozapine's impact on suicide risk and its tolerability, including hematologic, cardiovascular, and metabolic side effects.

Summary:

• Clozapine demonstrates consistent superiority over standard and novel antipsychotics for refractory positive symptoms in schizophrenia.
• Evidence suggests clozapine has a minimal risk of extrapyramidal symptoms (EPS) and may improve negative symptoms, though data on neurocognitive effects are limited.
• Studies indicate clozapine therapy can reduce suicidal behavior, but careful monitoring for adverse effects like neutropenia, seizures, and myocarditis is crucial.

Impact:

• Provides updated data to inform clinical management guidelines for schizophrenia treatment.
• Highlights clozapine's established efficacy and safety profile, guiding therapeutic decisions for complex cases.
• Emphasizes the importance of strict adherence to monitoring protocols to mitigate potential risks associated with clozapine therapy.